Figure 1 Patients cured of HCV infection

Slides:



Advertisements
Similar presentations
Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.
Advertisements

Hepatitis C in Minority Populations Andrea E. Reid, MD, MPH Veterans Affairs Medical Center Washington, DC.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.
Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Management of Chronic HCV Infection by PMDs Rod Rahimi Osler Journal Club
Hepatitis web study Hepatitis web study Boceprevir with PEG + RBV in Genotype 1 SPRINT-1 Phase 2 Treatment Naïve Kwo PY, et al. Lancet. 2010;376:
ELPA Symposium Compassionate Use in Hepatitis C Saving lives of patients who cannot wait Thomas Berg Section of Hepatology Clinic for Gastroenterology.
Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label,
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Where Are We on the Path to Elimination of Chronic Hepatitis C?
EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
HCV Care in Unique Patient Populations
Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 A stage-based approach to the treatment of NAFLD
Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Covering the Cover Gastroenterology
Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis 
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 HCV life cycle and site of action of DAAs
Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.
Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.
Figure 1 Definition and concept of ACLF
Figure 1 Host range of hepatitis E virus
Figure 2 Switching of biologic agents and biosimilars
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Figure 7 Example colonic high-resolution manometry
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Jordan J. Feld, Graham R. Foster  Journal of Hepatology 
Figure 1 Median coverage and distribution by
Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse 
in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)
Volume 155, Issue 5, Pages e2 (November 2018)
Division of Viral Hepatitis, CDC
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
A Guideline-Based Approach to HCV Care
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Volume 68, Issue 4, Pages (April 2018)
Volume 142, Issue 6, Pages (May 2012)
What Does the Future Hold and What Will It Mean for Patients?
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Distribution of markers of active HBV infection
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Genetic Factors and Hepatitis C Virus Infection
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
Hepatitis C treatment in patients with kidney disease
Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection  Harald Farnik, Christian M. Lange,
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Johannes Vermehren, James S. Park, Ira M. Jacobson, Stefan Zeuzem 
Treatment effectiveness by era.
Presentation transcript:

Figure 1 Patients cured of HCV infection Figure 1 | Patients cured of HCV infection. a | Graph shows cured patients as percentage of patients treated with the indicated regimens. Year in brackets indicates when the treatment was introduced. b | Absolute number of patients in the USA and worldwide who were cured by 2013 (Ref. 6). About 600,000 patients worldwide were treated with sofosbuvir-containing regimens by the end of 2015. Of the 185 million people worldwide infected with HCV, only a minority have been diagnosed. Green bars represent patients infected with HCV and orange bars represent cured patients. Cure is defined as achieving sustained virologic response. DAA, direct acting antivirals; RBV, ribavirin. Rehermann, B. (2016) Advances in hepatitis C research and treatment Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2015.227